Recombinant Human Vesicle-associated membrane protein-associated protein B/C (VAPB)

What is the basic structure of human VAPB protein?

Human VAPB is a C-tail-anchored (type II) ER membrane protein with a central coiled-coil domain and an N-terminal major sperm protein (MSP) domain (~125 residues) that faces the cytoplasmic side. The protein consists of an immunoglobulin-like β-sheet in its N-terminal domain, which shares approximately 22% sequence identity with the Ascaris suum major sperm protein. The structural arrangement facilitates VAPB's interaction with various intracellular proteins through its MSP domain while remaining anchored to the ER via its transmembrane domain .

How does VAPB differ from VAPA in terms of function and expression?

VAPA and VAPB share 63% sequence identity, primarily due to similarities in the MSP domain. While a clear functional difference between these paralogues has not been definitively established, they display tissue-specific RNA expression patterns during development. Both proteins are ubiquitously expressed in mammals, but their relative abundance varies across tissues and developmental stages. The functional redundancy between VAPA and VAPB may explain why some experimental knockdowns of VAPB alone show modest phenotypes—VAPA may compensate for some VAPB functions .

What cellular processes involve VAPB?

VAPB is involved in numerous crucial cellular processes:

• Organelle membrane tethering

• Lipid transfer between organelles

• Regulation of calcium homeostasis

• Autophagy

• Unfolded protein response (UPR)

• Potential extracellular functions through its cleaved and secreted MSP domain

Additionally, VAPB plays a role in maintaining membrane contact sites (MCS) between the ER and other organelles, facilitating the exchange of lipids and other molecules essential for cellular homeostasis .

What expression systems are most effective for producing functional recombinant human VAPB?

For recombinant human VAPB production, bacterial expression systems using E. coli BL21(DE3) are commonly employed for the soluble domains (particularly the MSP domain), while full-length VAPB with the transmembrane domain typically requires eukaryotic expression systems such as insect cells (Sf9 or High Five cells) with baculovirus or mammalian cells (HEK293 or CHO cells). When designing expression constructs, consider:

• For structural studies of the MSP domain: E. coli with a 6xHis-tag or GST-tag fusion followed by a protease cleavage site

• For full-length functional studies: Mammalian expression with C-terminal tags to avoid interference with the N-terminal MSP domain function

• For membrane integration studies: Codon optimization for the expression system is crucial for proper folding and membrane insertion

Expression Efficiency Comparison Table:

What purification strategies yield the highest purity recombinant VAPB for structural studies?

For high-purity recombinant VAPB suitable for structural studies, a multi-step purification strategy is recommended:

• Affinity chromatography using His-tag or GST-tag depending on the fusion protein design

• Tag cleavage using precision protease, followed by reverse affinity chromatography

• Ion exchange chromatography (typically Q-Sepharose) to separate charged variants

• Size exclusion chromatography as a final polishing step to achieve >95% purity

For membrane-bound full-length VAPB:

• Solubilization with mild detergents (DDM or LMNG at 1% w/v)

• Affinity purification in the presence of detergent

• Detergent exchange during size exclusion chromatography

Protein quality should be assessed using SDS-PAGE, Western blotting, and dynamic light scattering to confirm monodispersity before structural studies.

How can I design experiments to study VAPB interactions with binding partners?

To study VAPB interactions with binding partners, consider these methodological approaches:

• Co-immunoprecipitation assays: Express tagged recombinant VAPB in mammalian cells along with potential binding partners, then perform pull-down assays to identify interactions.

• Proximity labeling approaches: Use BioID or APEX2 fused to VAPB to identify proximal proteins in living cells.

• In vitro binding assays: Use purified recombinant VAPB (particularly the MSP domain) and potential binding partners in pull-down assays or surface plasmon resonance studies.

• FRET-based interaction studies: Create fluorescently labeled VAPB constructs to monitor real-time interactions in living cells.

• Yeast two-hybrid screening: Particularly useful for discovering novel binding partners using the MSP domain as bait.

For quantitative analysis, surface plasmon resonance or isothermal titration calorimetry can determine binding constants (Kd values) between VAPB and its partners .

How can recombinant VAPB be used to study ALS8-related pathogenic mechanisms?

The P56S mutation in VAPB causes amyotrophic lateral sclerosis type 8 (ALS8). To study pathogenic mechanisms:

• Protein aggregation studies: Compare wild-type and P56S recombinant VAPB using:

  • Thioflavin T fluorescence assays to monitor aggregate formation kinetics

  • Electron microscopy to visualize aggregate structures

  • Dynamic light scattering to measure aggregate size distributions

  • FTIR or circular dichroism to assess secondary structure changes

• Cellular models: Express fluorescently tagged wild-type or P56S VAPB in neuronal cells to:

  • Track aggregate formation using live-cell imaging

  • Assess ER stress response using UPR-responsive luciferase reporters

  • Measure calcium homeostasis disruption using calcium-sensitive dyes

  • Evaluate protein-protein interaction disruptions using proximity labeling

• Binding partner disruption: Use pull-down assays with recombinant wild-type versus P56S VAPB to identify differential binding to partners, followed by validation in cellular models.

Studies have shown that P56S VAPB forms insoluble cytosolic aggregates in neuronal and non-neuronal cells, inducing the formation of membranous aggregates consisting of stacked ER cisternae. Importantly, these VAPB P56S-induced aggregates form rapidly (within 2 hours) compared to SOD1 aggregates that take days to develop .

What are the approaches to study VAPB's role in membrane contact sites between organelles?

To investigate VAPB's role in membrane contact sites (MCS):

• Proximity-based labeling: Use split-fluorescent proteins or FRET pairs to visualize MCS in living cells, with one half fused to VAPB and the other to a partner protein on the opposing membrane.

• Electron microscopy: Immunogold labeling of VAPB to visualize its localization at MCS at ultrastructural resolution.

• Reconstitution systems: Create artificial membrane systems with purified recombinant VAPB and its binding partners to study minimal requirements for MCS formation.

• Domain mapping: Use truncated versions of recombinant VAPB to determine which domains are necessary for MCS formation and maintenance.

• Lipid transfer assays: Develop fluorescent lipid transfer assays to measure VAPB-dependent lipid exchange between membranes in vitro.

Experimental Data Table: Effect of VAPB Depletion on Inter-organelle Distances

How can recombinant VAPB help elucidate mechanisms of viral hijacking of host cells?

Viruses like Hepatitis C virus (HCV) hijack VAPB for their replication. To study this process:

• Protein-protein interaction mapping: Use recombinant VAPB domains to identify binding regions for viral proteins (e.g., HCV NS5A and NS5B).

• Structural studies: Employ X-ray crystallography or cryo-EM to solve structures of VAPB-viral protein complexes.

• Competitive inhibition assays: Design peptides based on viral protein binding sites to competitively inhibit virus-VAPB interactions.

• Reconstitution of lipid transfer: Create in vitro systems with recombinant VAPB, OSBP, and viral proteins to reconstitute lipid transfer events.

• CRISPR/Cas9 engineering: Generate VAPB mutants resistant to viral protein binding to confirm interaction significance.

HCV NS5B interacts via its C-terminal auto-regulatory motif with the MSP domain of VAPA/B. The viral protein NS5A also forms a complex with VAP-MSP through its disordered C-terminal D3 domain. These interactions facilitate the formation of a phosphoinositide cycle between the ER and HCV double-membrane vesicles (DMVs), involving VAP, NIR2, and OSBP, which helps create an environment conducive to viral replication .

What are common pitfalls when working with recombinant VAPB and how can they be addressed?

Common challenges and solutions when working with recombinant VAPB include:

• Poor solubility of full-length protein:

  • Solution: Use mild detergents like DDM (0.1-0.5%), LMNG (0.01-0.05%), or nanodiscs for stabilization

  • Alternative: Focus on the soluble MSP domain for interaction studies

• Aggregation during purification:

  • Solution: Include reducing agents (5mM DTT or 2mM TCEP) throughout purification

  • Solution: Purify at lower temperatures (4°C) and use glycerol (10-15%) in buffers

• Loss of function after recombinant expression:

  • Solution: Verify proper folding using circular dichroism or limited proteolysis

  • Solution: Test activity with known binding partners using pull-down assays

• Inconsistent cellular localization of overexpressed VAPB:

  • Solution: Use low expression levels or inducible systems

  • Solution: Confirm C-terminal positioning of tags to maintain proper ER localization

• Difficult detection in Western blots:

  • Solution: Optimize sample preparation by avoiding boiling (heat at 70°C for 10 minutes)

  • Solution: Use specialized membrane protein extraction buffers containing 1% SDS or 8M urea

How should contradictory data regarding VAPB function be interpreted and resolved?

When facing contradictory data in VAPB research:

• Consider cell type-specific effects:

  • Test hypotheses across multiple cell lines to determine if contradictions are cell type-dependent

  • Document expression levels of VAPA and other MSP-domain proteins that might compensate

• Evaluate protein tag interference:

  • Compare N-terminal vs. C-terminal tags to identify potential functional interference

  • Use multiple tag types (His, FLAG, GFP) to verify consistent results

• Assess knockdown efficiency:

  • For siRNA/shRNA experiments, quantify VAPB reduction at both mRNA and protein levels

  • Consider compensatory upregulation of VAPA in VAPB knockdown experiments

• Standardize experimental conditions:

  • Control for cell density, passage number, and transfection efficiency

  • Document exact buffer compositions and experimental timelines

• Employ multiple methodological approaches:

  • Verify key findings using orthogonal techniques (e.g., both imaging and biochemical approaches)

  • Consider in vitro reconstitution to test direct effects vs. cellular complexity

The literature shows discrepancies regarding which proteins associate with mutant VAPB aggregates, with some studies showing association of ER luminal proteins while others show exclusion. These contradictions may be attributed to differences in cell lines, VAPB expression levels, and the exclusion of some ER membrane proteins from the aggregates .

What are the best assays to quantitatively measure VAPB-dependent lipid transfer between membranes?

To quantitatively measure VAPB-dependent lipid transfer:

• Fluorescent lipid transfer assays:

  • Use donor liposomes containing fluorescent lipids (NBD-ceramide, NBD-cholesterol)

  • Measure transfer to acceptor liposomes via fluorescence dequenching

  • Include recombinant VAPB and binding partners (CERT, OSBP) to measure facilitated transfer

• Radioactive lipid transfer assays:

  • Incorporate 3H or 14C-labeled lipids in donor membranes

  • Separate donor and acceptor membranes after incubation

  • Quantify radioactivity transfer by scintillation counting

• FRET-based real-time assays:

  • Label donor and acceptor membranes with FRET pairs

  • Measure FRET changes as lipids transfer between membranes

  • Calculate transfer rates under different conditions (±VAPB, ±binding partners)

• Mass spectrometry-based assays:

  • Use isotope-labeled lipids in donor membranes

  • After incubation with VAPB and binding partners, extract lipids from acceptor membranes

  • Quantify transferred lipids using LC-MS/MS

Lipid Transfer Rate Comparison Table:

What are promising approaches to target VAPB for therapeutic applications in ALS and other diseases?

Emerging therapeutic approaches targeting VAPB include:

• Small molecule stabilizers: Developing compounds that stabilize wild-type VAPB conformation or prevent P56S VAPB aggregation.

• Peptide-based inhibitors: Designing peptides that mimic FFAT motifs to competitively inhibit pathological interactions or promote beneficial ones.

• Gene therapy approaches:

  • Antisense oligonucleotides to reduce expression of mutant VAPB

  • CRISPR-based gene editing to correct the P56S mutation

  • Overexpression of molecular chaperones to reduce aggregate formation

• Upregulation of compensatory mechanisms:

  • Enhancing VAPA expression to compensate for VAPB dysfunction

  • Modulating UPR pathways to improve cellular resilience

• Modulation of lipid metabolism:

  • Targeting downstream lipid imbalances caused by VAPB dysfunction

  • Developing lipid nanoparticles to restore normal lipid distributions

How can advanced imaging techniques be optimized for studying VAPB dynamics at membrane contact sites?

Advanced imaging approaches for VAPB at membrane contact sites:

• Super-resolution microscopy:

  • STED or STORM imaging of fluorescently tagged VAPB to visualize nanoscale distribution

  • Single-particle tracking to monitor VAPB mobility at contact sites

  • Optimization parameters: fluorophore selection (Janelia Fluor dyes provide superior brightness), buffer composition (oxygen scavenging systems improve photostability), and fixation protocols (mild PFA fixation preserves MCS structure)

• Correlative light and electron microscopy (CLEM):

  • Combine fluorescence imaging of VAPB with EM ultrastructure analysis

  • Use nanogold-conjugated antibodies for precise localization

  • Critical factors: sample preparation to minimize artifact formation during processing

• Live-cell dynamic imaging:

  • FRAP (Fluorescence Recovery After Photobleaching) to measure VAPB turnover at MCS

  • Split-fluorescent protein approaches to visualize MCS formation in real-time

  • Key considerations: minimizing laser power to prevent phototoxicity, temperature control for physiological dynamics

• Expansion microscopy:

  • Physical expansion of samples to achieve super-resolution with standard confocal microscopy

  • Optimization needed for membrane proteins: gentle digestion protocols, anchoring strategies

• In situ cryo-electron tomography:

  • Direct visualization of VAPB at MCS in near-native state

  • Correlative approaches with cryo-fluorescence to identify regions of interest

What experimental models best represent VAPB function in complex multicellular contexts?

Advanced experimental models for studying VAPB in complex contexts:

• Human iPSC-derived organoids:

  • Brain organoids from ALS patient-derived iPSCs carrying VAPB mutations

  • Liver organoids to study VAPB's role in lipid metabolism and viral infections

  • Critical factors: maturation protocols, reproducibility between batches

• Conditional knockout animal models:

  • Tissue-specific and inducible VAPB knockout mice to study temporal effects

  • Double VAPA/VAPB knockout to overcome functional redundancy

  • Key considerations: promoter selection for tissue specificity, validation of knockout efficiency

• Humanized mouse models:

  • Knock-in of human VAPB P56S mutation to recreate ALS8 pathology

  • Advantages over simpler overexpression models: physiological expression levels, proper regulation

• Advanced cell culture systems:

  • Co-culture systems combining neurons with glial cells or hepatocytes with immune cells

  • Microfluidic devices to study VAPB function under mechanical stress or in microenvironments

  • 3D cell culture using extracellular matrix to better mimic tissue architecture

• CRISPR screens in complex models:

  • Genome-wide or targeted CRISPR screens to identify genetic modifiers of VAPB function

  • Application in iPSC-derived cells or organoids for tissue-specific contexts

These advanced models can help bridge the gap between simplified in vitro systems and the complexity of human disease, providing more translatable insights into VAPB biology and pathology.